Table III.
Examples of Clinical Trials Being Performed with siRNA Designed Against Molecular Targets of Ocular Diseases (http://www.clinicaltrials.gov/ct2/results?term-siRNA)
| Company (Sponsor) | siRNA product | Disease | Administration | Phase | First received and last updated | Status |
|---|---|---|---|---|---|---|
| Opko Health, Inc. | Cand5 | AMD | Intravitreal injection | Phase II | Nov 30, 2005 | Completed |
| Aug 4, 2008 | ||||||
| Opko Health, Inc. | Cand5 (bevasiranib) | DR | Intravitreal injection | Phase II | Mar 23, 2006 | Completed |
| July 24, 2008 | ||||||
| Allergan | Sirna-027 | AMD | Intravitreal injection | Phase I | Aug 10, 2006 | Completed |
| CNV | Phase II | Aug 14, 2008 | ||||
| Allergan | Sirna-027 | AMD | Intravitreal injection | Phase II | Oct 31, 2006 | Terminated |
| CNV | Aug 7, 2009 | |||||
| Opko Health, Inc. | Compare bevasiranib and Lucentis® | AMD | Intravitreal injection | Phase III | Nov 13, 2007 | Withdrawn prior to enrollment |
| Jun 16, 2011 | ||||||
| Quark Pharmaceuticals | QPI-1007 | Chronic Optic Nerve Atrophy | Intravitreal injection | Phase I | Feb 4, 2010 | Active, not recruiting participants |
| Apr 24, 2012 | ||||||
| Sylentis, SA | SYL040012 | Glaucoma | Topical administration | Phase I | Oct 21, 2010 | Completed |
| Ocular hypertension | Phase II | Sep26, 2012 | ||||
| Sylentis, SA | SYL1001 | Dry eye | Topical administration | Phase I | Sep 14, 2011 | Completed |
| Ocular pain | Jul 16, 2012 |
AMD Age-related macular degeneration
DR Diabetic retinopathy
CNV Choroidal ocular neovascularization